Anlotinib plus whole-brain radiation for SCLC brain metastases
Treatments studied
Part of Brain & nervous system, Cancer clinical trials.
This trial tests whether combining Anlotinib (a targeted drug that blocks tumor blood vessel growth) with whole-brain radiation can better control brain metastases in small cell lung cancer patients. It is for people with up to 10 brain tumors who have not had brain radiation before.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have small cell lung cancer that has spread to the brain (up to 10 tumors).
- Your doctor expects you to live at least 3 more months.
- Your organs and bone marrow must be working well enough (checked by blood tests).
- If you could become pregnant, you must use effective birth control during the study and for 6 months after.
- You cannot have had brain radiation before.
- You cannot have used antiangiogenic drugs (like certain targeted therapies) in the past month.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of radiation therapy and a targeted drug (Anlotinib) for people with a type of advanced lung cancer that cannot be treated with standard chemoradiation. It may help if your cancer has not spread to other parts of the body and you have not had certain prior treatments.
This trial tests a combination of the targeted drug bemotuzumab, chemotherapy, and anlotinib (which blocks blood vessel growth) followed by radiation therapy for people with extensive-stage small cell lung cancer who haven't had treatment yet. The goal is to see if this approach helps control the cancer.
This trial tests a combination of focused radiation (stereotactic radiosurgery) and an oral targeted therapy called anlotinib for people with non-small cell lung cancer that has spread to the brain. It may offer a way to control brain metastases without more invasive procedures.
This trial tests whether adding anlotinib (a targeted therapy) to standard radiation can better control breast cancer that has spread to the brain. It is for people with HER2-negative breast cancer and at least one brain tumor seen on MRI.
This trial tests a new radiation approach for people with small cell lung cancer that has spread to the brain. It combines whole-brain radiation that avoids the memory centers, followed by focused radiation to the tumors, while you also receive standard chemotherapy and immunotherapy.
This trial tests whether combining brain radiation with chemotherapy and immunotherapy can help people with advanced lung cancer that has spread to the brain but has not yet been treated. It is for those whose tumors do not have certain gene mutations (EGFR, ALK, ROS1).
Hear when a new Whole-Brain Radiotherapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.